Treatment
Prevnar® clinical trials
We’re tracking 7 recruiting studies that include Prevnar®, each written for real people, not researchers, below.
Recruiting studies
- NCT05170399RecruitingPhase 4
Testing how cancer vaccines work in B-cell blood cancers
This study measures how well certain vaccines stimulate the immune system in people with B-cell blood cancers such as CLL and different types of lymphoma or Waldenström macroglobulinemia. It may help doctors better predict who will benefit most from vaccination and improve vaccine planning for these conditions.
Bethesda, MarylandAges 18–90 - NCT07160244RecruitingPhase 3
GBS vaccine study for healthy pregnant women and their babies
This study tests a vaccine against Group B Streptococcus (GBS) during pregnancy to see if it can protect newborns from infection. Healthy pregnant women with a single baby can join.
Birmingham, AlabamaAges 1 day–49 years - NCT07168915RecruitingPhase 1
Safety study of an experimental vaccine in healthy adults
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
Hallandale, FloridaAges 18–49 - NCT03942328RecruitingPhase 1/Phase 2
Immune cell vaccine plus checkpoint treatment after liver radiation
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Rochester, MinnesotaAges 18 years+ - NCT06617715RecruitingPhase 3
Pneumonia vaccine trial for infants and children
This trial tests a 13-valent pneumococcal conjugate vaccine to prevent pneumonia and serious infections caused by pneumococcus bacteria. It may be a good option if your child has never had a pneumococcal vaccine before.
Zhengzhou, HenanAges 1 month–5 years - NCT06800261RecruitingPhase 1
Testing a new pneumonia vaccine for babies 2-23 months old
This study tests a new pneumococcal vaccine (PCV24) for babies ages 2 to 23 months. It aims to see if the vaccine is safe and helps protect against serious infections like pneumonia and meningitis.
Jinan, ShandongAges 1 month–1.9 years - NCT07300644RecruitingPhase 2
Pneumococcal vaccine trial for infants and children up to 5 years
This trial tests a new pneumococcal vaccine (PCV24) in healthy infants and children. It aims to protect against serious infections like pneumonia and meningitis caused by pneumococcal bacteria.
Huanggang, HubeiAges 1 month–5 years
What Prevnar® is being studied for
Conditions with recruiting Prevnar® studies.
Common questions
- Are there clinical trials studying Prevnar®?
- Yes. Clin2 currently lists 7 recruiting studies that include Prevnar®, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Prevnar® trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Prevnar® an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Prevnar® or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.